

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

**POLL RESULTS OF
THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
HELD ON JANUARY 10, 2024**

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that, at the 2024 first extraordinary general meeting of the Company (the “**EGM**”) held at 2:00 p.m. on Wednesday, January 10, 2024 at Fuyu Hall, B1, Tower A, Coolpad Building, No. 2 Mengxi Road, North District, High-tech Industrial Park, Nanshan District, Shenzhen, the PRC, the proposed resolution set out in the notice of the EGM was passed by way of poll.

References are made to the notice of the EGM and the circular of the Company dated December 18, 2023 (the “**Circular**”) in relation to the proposed amendments to the articles of association and related rules of procedures of the Company. Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The executive directors of the Company: Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company: Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming, attended the EGM, in person or by electronic means.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of Shares in issue is 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). No Shareholder was required to abstain from voting on the resolutions under the Listing Rules. There was no Share entitling the holder to attend the meeting and abstain from voting in favour of the resolutions under Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

The total number of Shares entitling the holders to attend and vote on the resolutions at the EGM was 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 917,012,219 Shares (including 905,958,943 A Shares and 11,053,276 H Shares), representing approximately 62.50% of the total number of Shares.

The poll results in respect of the resolution at the EGM are set out below:

NO.	SPECIAL RESOLUTION	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1	The resolution regarding the amendments to the articles of association and related rules and procedures of the Company	898,355,976 97.97%	18,455,443 2.01%	200,800 0.02%

As more than two-third of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolution, the resolution was duly passed as special resolution.

Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of the H Shares at the EGM. The convening of the EGM was in compliance with the Company Law of the People's Republic of China and the Articles.

AMENDMENTS TO THE ARTICLES

The Board is pleased to announce that the proposed amendments to the Articles and related rules and procedures of the Company were duly approved by the Shareholders at the EGM. The proposed amendments to the Articles and related rules and procedures of the Company have taken effect on January 10, 2024.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
January 10, 2024

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.